» Articles » PMID: 22117642

Autoimmune Liver Diseases in Children - What is Different from Adulthood?

Overview
Publisher Elsevier
Specialty Gastroenterology
Date 2011 Nov 29
PMID 22117642
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune liver disorders in childhood include autoimmune hepatitis, autoimmune sclerosing cholangitis and de novo autoimmune hepatitis after liver transplant. These inflammatory liver disorders are characterised histologically by interface hepatitis, biochemically by elevated transaminase levels and serologically by autoantibodies and increased levels of immunoglobulin G. Autoimmune hepatitis is particularly aggressive in children and progresses rapidly unless immunosuppressive treatment is started promptly. With appropriate treatment 80% of patients achieve remission and long-term survival. Autoimmune sclerosing cholangitis responds to the same treatment used for autoimmune hepatitis in regards to parenchymal inflammation, but bile duct disease progresses in about 50% of cases, leading to a worse prognosis and higher transplantation requirement; it has a high recurrence rate post-liver transplant. De novo autoimmune hepatitis after liver transplant affects children transplanted for non-autoimmune conditions and responds well to the same treatment schedule used for autoimmune hepatitis, but not to the schedule used for acute rejection.

Citing Articles

Retrospective, single-center analysis of autoimmune hepatitis in Jordanian children: clinical features, treatments, and outcomes.

Altamimi E, Al Omari D, Obeidat H, Barham K BMC Pediatr. 2024; 24(1):102.

PMID: 38331749 PMC: 10851525. DOI: 10.1186/s12887-024-04590-9.


Post-Transplant Immunosuppression in Autoimmune Liver Disease.

Kelly C, Zen Y, Heneghan M J Clin Exp Hepatol. 2023; 13(2):350-359.

PMID: 36950491 PMC: 10025678. DOI: 10.1016/j.jceh.2022.07.002.


Serum Matrix Metalloproteinase 7 Is a Diagnostic Biomarker of Biliary Injury and Fibrosis in Pediatric Autoimmune Liver Disease.

Lam S, Singh R, Dillman J, Trout A, Serai S, Sharma D Hepatol Commun. 2020; 4(11):1680-1693.

PMID: 33163837 PMC: 7603534. DOI: 10.1002/hep4.1589.


Approach to the patient with acute severe autoimmune hepatitis.

Rahim M, Miquel R, Heneghan M JHEP Rep. 2020; 2(6):100149.

PMID: 32995712 PMC: 7509236. DOI: 10.1016/j.jhepr.2020.100149.


Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response.

Agina H, Ehsan N, Abd-Elaziz T, Abd-Elfatah G, Said E, Sira M Clin Exp Hepatol. 2019; 5(3):256-264.

PMID: 31598564 PMC: 6781821. DOI: 10.5114/ceh.2019.87642.